SCHEMBL7689558

SCHEMBL7689558

CC(=O)NCC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccc(NS(=O)(=O)c2ccc3ccccc3c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC10 Q969S8 1/20 0.52
HDAC11 Q96DB2 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
HDAC9 Q9UKV0 1/20 0.52
HDAC5 Q9UQL6 1/20 0.52
CA2 P00918 3/20 0.50
PLAU P00749 2/20 0.48
GPR27 Q9NS67 1/20 0.48
CA1 P00915 2/20 0.46
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7695272 0.93 ALDH1A1 (0.52) ALDH1A1LMNAGAASMN1; SMN2HDAC3
SCHEMBL7695396 0.91 AKR1C3 (0.48) ALDH1A1LMNAGAASMN1; SMN2HDAC3
SCHEMBL7706585 0.89 ALDH1A1 (0.53) ALDH1A1LMNAGAASMN1; SMN2HDAC3
SCHEMBL7703565 0.88 CA2 (0.51) ALDH1A1LMNAGAASMN1; SMN2HDAC3
SCHEMBL7654043 0.86 ALDH1A1 (0.54) ALDH1A1LMNAGAASMN1; SMN2HDAC3
SCHEMBL7694334 0.81 ALDH1A1 (0.49) ALDH1A1HDAC2HDAC8HDAC6MEN1
SCHEMBL7665000 0.81 ALDH1A1 (0.52) ALDH1A1LMNAGAASMN1; SMN2HDAC3
SCHEMBL7689353 0.81 ALDH1A1 (0.44) ALDH1A1LMNASMN1; SMN2HDAC1MEN1
SCHEMBL7694179 0.80 AKR1C3 (0.48) ALDH1A1LMNAGAASMN1; SMN2CA2
SCHEMBL7695356 0.80 SLC16A3 (0.48) CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436925-B1 BETTER ABLE TO CROSS MEMBRANES; INHIBITORS OF CYSTEINE PROTEASES LIKE CALPAIN I AND II AND CATHEPSIN B AND L, CAN THUS BE USED TO CONTROL DISEASES ASSOCIATED WITH AN ELEVATED ACTIVITY OF CALPAIN ENZYMES OR CATHEPSIN ENZYMES ABBOTT LABORATORIES 2002-08-20 US disclosed